Amylyx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application (NDA) for AMX0035 for the Treatment of ALS

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for AMX0035 (so… Read full article

Leave a comment

Your email address will not be published. Required fields are marked *